Market Research Report
Psoriasis - 5EU Drug Forecast and Market Analysis to 2024
|Published by||GlobalData||Product code||365842|
|Published||Content info||213 Pages
Delivery time: 1-2 business days
|Psoriasis - 5EU Drug Forecast and Market Analysis to 2024|
|Published: April 13, 2016||Content info: 213 Pages||
Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients.
GlobalData projects the Psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies- interleukin-17 (IL-17) inhibitors (Cosentyx, guselkumab and tildrakizumab), interleukin-23 (IL-23) inhibitors (ixekizumab and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla (apremilast). Nevertheless, looming patent expiries of high-grossing branded drugs- especially TNF inhibitors, Humira, Enbrel and Remicade, in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with rapid global developmentsof biosimilars are expected to spread the growth throughout the different classes of products, away from the branded TNF inhibitors which have traditionally been the main driver of growth in the prior years.
The 5EU contributed 31.6% of the global market share in the psoriasis market in 2014. Similarly to the US, the drug classes spanning the 5EU psoriasis market were: TNF inhibitors, an IL-12/IL-23 inhibitor, IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors, a PDE-4 inhibitor, systemic therapies, biosimilars, and topical therapies.